Elixir Medical Announces Excellent, 3-Year Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System

Successful Live Case of DESolve® 100 implantation at Elixir Symposium at EuroPCR 2015 Sunnyvale, Calif. – May 20, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced excellent 3-year imaging results from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve® Novolimus Eluting Coronary Scaffold […]